Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT01452126
Other study ID # UNM HRRC 11-030
Secondary ID
Status Suspended
Phase Phase 2
First received October 11, 2011
Last updated December 18, 2013
Start date June 2011
Est. completion date June 2014

Study information

Verified date December 2013
Source University of New Mexico
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a dose finding study to identify the minimum effective anesthetic concentration (MEAC) of ropivacaine to produce insensate body parts sufficient for surgery in supraclavicular and infraclavicular approaches to the brachial plexus, parasacral and popliteal approaches to the sciatic nerve, femoral nerve and transversus abdominis plane (TAP) blocks in adults.


Recruitment information / eligibility

Status Suspended
Enrollment 20
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- American Society of Anesthesiologists physical status I to III (patients may be healthy or have systemic disease, but any disease does not pose a constant threat to life, and patients are neither moribund, nor not expected to survive without the operation).

- Age 18 or above

- Undergoing elective ambulatory surgery of the upper limb (excluding the shoulder), lower limb (excluding the hip), or lower abdomen with sensory blockade as part of the pain management plan.

Exclusion Criteria:

- Body mass index of >35 kg/m2 (higher chance of failure)

- Deformities of the leg (for patients in the parasacral, femoral, and popliteal groups), or the chest or shoulder (for patients in the supraclavicular, infraclavicular, and TAP groups)

- Preexisting infection at the injection site

- Existing neurologic disease

- Allergy to local anesthetic agents

- Severe respiratory disease

- Coagulopathy

- Any other contraindication to the block being considered

- Patients requiring total motor blockade as well as sensory blockade

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)


Related Conditions & MeSH terms


Intervention

Drug:
Ropivacaine concentration
Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block

Locations

Country Name City State
United States Univeristy of Mexico Outpatient Surgical and imaging service Albuquerque New Mexico

Sponsors (2)

Lead Sponsor Collaborator
University of New Mexico University of Toronto

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary effective concentration of ropivacaine to produce surgical anesthesia in 50% of population The concentration of ropivacaine for each block will be determined by the success or failure to establish surgical anesthesia within the allocated time frame of the previous patient as per Dixon and Massey's up-and-down sequential allocation method to determine the effective concentration of ropivacaine in 50% of the population 1 year No
Secondary Number of patients with complications and duration of action All patients are followed up for complications such as bleeding, infection, side effects, nerve damage and the duration of the block 1 year Yes